Abstract

Background: Chagas cardiomyopathy is caused by Trypanosoma cruzi (Tc). Two antigenic candidates, TcG2 and TcG4, are recognized by antibodies in naturally infected dogs and humans; and these vaccine candidates provided protection from Tc infection in mice and dogs. Trypanosoma rangeli (Tr) is non-pathogenic to mammals and shown to elicit cross-reactive anti-Tc antibodies. In this study, we investigated if fixed Tr (fTr) can further enhance the efficacy of the TcG2/TcG4 DNA vaccine.Methods and Results: C57BL/6 mice were immunized with TcG2/TcG4 DNA vaccine and fTr (delivered as an adjuvant or in prime-boost approach), and challenged with Tc. Serology studies showed that fTr (±quil-A) elicited Tc- and Tr-reactive IgGs that otherwise were not stimulated by TcG2/TcG4 vaccine only, and quil-A had suppressive effects on fTr-induced IgGs. After challenge infection, TcG2/TcG4-vaccinated mice exhibited potent expansion of antigen- and Tc-specific IgGs that were not boosted by fTr±quil-A. Flow cytometry analysis showed that TcG2/TcG4-induced dendritic cells (DC) and macrophages (Mφ) responded to challenge infection by expression of markers of antigen uptake, processing, and presentation, and production of pro-inflammatory cytokines. TcG2/TcG4-induced CD4+T cells acquired Th1 phenotype and expressed markers that orchestrate adaptive immunity. A fraction of vaccine-induced CD4+T cells exhibited iTreg phenotype responsible for aversion of self-injurious immune responses. Further, TcG2/TcG4-vaccinated mice exhibited potent expansion of poly-functional CD8+T cells with TNF-α/IFN-γ production and cytolytic phenotype post-infection. Subsequently, tissue parasites and pathology were hardly detectable in TcG2/TcG4-vaccinated/infected mice. Inclusion of fTr±quil-A had no clear additive effects in improving the Tc-specific adaptive immunity and parasite control than was noted in mice vaccinated with TcG2/TcG4 alone. Non-vaccinated mice lacked sufficient activation of Th1 CD4+/CD8+T cells, and exhibited >10-fold higher levels of tissue parasite burden than was noted in vaccinated/infected mice.Conclusion: TcG2/TcG4 vaccine elicits highly effective immunity, and inclusion of fTr is not required to improve the efficacy of DNA vaccine against acute Tc infection in mice.

Highlights

  • Chagas cardiomyopathy, caused by Trypanosoma cruzi, is a major health concern in Latin America and it is an emerging disease in the United States, Europe, Japan, and other countries [1]

  • We first monitored if fixed T. rangeli (fTr), delivered as an adjuvant or as an antigen in prime-boost approach, modulates the TcG2/TcG4 DNA vaccine—induced antibody response in mice

  • TcG2/TcG4 vaccine adjuvanted with fTr resulted in maximal levels of Tcspecific immunoglobulin G (IgG) sub-types (IgG1, IgG2a, and IgG2b) while co-delivery of quil A (QA) had a suppressive effect on Trypanosoma cruzi (Tc)-specific IgG subtypes stimulated by TcG2/TcG4 vaccine adjuvanted with fTr (∧p < 0.001, compare gp2 and gp4) or boosted with fTr (∧p < 0.05, compare gp5 and gp6) (Figures 1E–G)

Read more

Summary

Introduction

Chagas cardiomyopathy, caused by Trypanosoma cruzi, is a major health concern in Latin America and it is an emerging disease in the United States, Europe, Japan, and other countries [1]. We have screened several candidate antigens, and selected TcG1, TcG2, and TcG4 for further development as potential vaccine candidates These antigens are phylogenetically conserved in clinically important T. cruzi strains, expressed in infective and intracellular stages of the parasite, and recognized by parasitespecific cellular and humoral immune responses in multiple T. cruzi-infected hosts [4,5,6,7]. Recent studies have tested several other antigenic candidates as vaccine for their prophylactic and therapeutic efficacy against Chagas disease. Results of these vaccines are encouraging and summarized in recent reviews [13,14,15]. We investigated if fixed Tr (fTr) can further enhance the efficacy of the TcG2/TcG4 DNA vaccine

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.